EATRIS brings together resources and services for research communities to translate scientific discoveries into benefits for patients. Our infrastructure’s resources are therefore highly relevant for the research community in the context of the COVID-19 pandemic caused by the SARS-CoV-2 virus.
What COVID-19-related expertise and services can EATRIS offer?
- 2019-nCoV challenge studies in Non-Human Primates (NHPs) under BSL3+
- Advanced preclinical models including NHPs, with advanced analytical readouts including molecular and structural imaging (including real-time imaging of lung lesions), available under BSL 3 conditions
- Immunomonitoring and virological assays
- High throughput screening supporting diagnostics, genotyping, phenotyping and drug repurposing
- Clinical isolation units
- Expertise on pharmacology and protein-drug interaction modelling
- Regulatory support, including scientific advice procedure with the European Medicines Agency or national authorities
The EATRIS COVID-19 services listed here are available for any researcher or research team (academic or industrial) that is developing a potential therapy, vaccine or tool for use against the current COVID-19 pandemic, with secured funding. EATRIS can also connect you with the right partners if you are preparing a funding proposal.
Research requests are handled via a single point of contact (David Morrow; details below), with a targeted turnaround time of 48 hours or less. This means that applicants receive details of available services and suppliers within two days of the first request.